Decipher Labs

Why is Decipher Labs Ltd falling/rising?

As of 01-Sep, Decipher Labs Ltd's stock price is declining at 5.40, with a total drop of -48.33% year-to-date and significant underperformance across various time frames. The stock's bearish trend is compounded by financial losses and low return on equity, despite increased investor participation.

As of 01-Sep, Decipher Labs Ltd's stock price is falling, currently at 5.40, reflecting a change of -0.09 or -1.64%. The stock has been on a downward trend, having underperformed the sector by -1.04% today and experiencing consecutive falls for the last two days, resulting in a total decline of -7.69% during this period. <BR><BR>The company's performance over various time frames also indicates significant underperformance. Over the past week, the stock has decreased by -5.10%, and in the last month, it has fallen by -14.69%. Year-to-date, the decline is even more pronounced at -48.33%, while the one-year return shows a decrease of -47.83%. This consistent underperformance is further highlighted by the stock's returns over the last three years, where it has generated -65.67%, contrasting sharply with the +17.67% return of the benchmark Sensex.<BR><BR>Additionally, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. The company's financial health is also a concern, as it has reported operating losses and a negative EBITDA of Rs. -2.24 cr, which contributes to its weak long-term fundamental strength. The return on equity is low at 9.42%, and the company has shown a significant decline in net sales and profit after tax over the past nine months.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 273.68% against the 5-day average, the overall outlook remains negative due to the company's ongoing financial struggles and consistent underperformance against benchmarks.

Who are in the management team of Decipher Labs?

The management team of Decipher Labs consists of Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary & Compliance Officer).

The management team of Decipher Labs includes the following individuals:<BR><BR>1. **Sushant Mohan Lal** - Executive Director<BR>2. **G Venkateswara Rao** - Independent Director<BR>3. **Megha Agarwal** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Decipher Labs do?

Decipher Labs Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, was established in 1986 and reported net sales of 2 Cr and a net loss of 2 Cr for June 2026. The company has a market cap of INR 6 Cr and operates under the name Decipher Labs since February 2020.

Overview: <BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Decipher Labs Ltd was initially incorporated as Combat Drugs Private Limited in September 1986. It transitioned to a Public Limited Company and changed its name to Combat Drugs Limited in June 1992. The company was renamed Decipher Labs Limited on February 12, 2020. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 2 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.01 <BR>Return on Equity: -20.85% <BR>Price to Book: 0.29<BR><BR>Contact Details: <BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

Who are the peers of the Decipher Labs?

Decipher Labs' peers include Unjha Formul, Ortin Global, Beryl Drugs, Brawn Biotech, Ganga Pharma, Vivanza Biosci, Fabino Enter, and Shyama Computro. Unjha Formul shows the best management and return metrics, while Decipher Labs has the lowest 1-year return at -48.50%.

Peers: The peers of Decipher Labs are Unjha Formul., Ortin Global, Beryl Drugs, Brawn Biotech, Ganga Pharma., Vivanza Biosci., Fabino Enter, and Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Decipher Labs and the rest. Below Average management risk is noted for Ortin Global, Beryl Drugs, Brawn Biotech, Ganga Pharma., Vivanza Biosci., Fabino Enter, and Shyama Computro. Growth is Below Average for Ortin Global, Beryl Drugs, Brawn Biotech, and Fabino Enter, while Decipher Labs, Ganga Pharma., and the rest also show Below Average growth. Average growth is seen at Vivanza Biosci. Capital Structure is Good at Unjha Formul., Average at Ganga Pharma., and Below Average for the rest.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 10.70%, while Decipher Labs has the lowest at -48.50%. Compared to Decipher Labs, all peers have a significantly better 1-year return. Additionally, Ortin Global, Beryl Drugs, Brawn Biotech, Vivanza Biosci., and Decipher Labs have negative six-month returns.

How big is Decipher Labs?

As of 31st August, Decipher Labs Ltd has a market capitalization of 6.00 Cr and reported net sales of 13.53 Cr with a net loss of 3.07 Cr over the latest four quarters. Shareholder's funds were 22.86 Cr and total assets were valued at 23.89 Cr as of March 2025.

As of 31st August, Decipher Labs Ltd has a market capitalization of 6.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 13.53 Cr. However, the company experienced a loss of 3.07 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where shareholder's funds amounted to 22.86 Cr and total assets were valued at 23.89 Cr.

Which are the latest news on Decipher Labs?

Should I buy, sell or hold Decipher Labs Ltd?

When is the next results date for Decipher Labs Ltd?

The next results date for Decipher Labs Ltd is 13 August 2026.

The next results date for Decipher Labs Ltd is scheduled for 13 August 2026.

Are Decipher Labs Ltd latest results good or bad?

Decipher Labs Ltd's latest results are concerning, showing a net loss of ₹0.36 crores in Q4 FY26, a 33.33% increase in losses from the previous quarter, despite a slight revenue increase. The company continues to struggle with profitability and operational efficiency, raising doubts about its long-term viability.

Decipher Labs Ltd's latest results present a mixed picture, leaning more towards negative than positive. In Q4 FY26, the company reported a net loss of ₹0.36 crores, which is a 33.33% increase in losses compared to the previous quarter. While there was a slight improvement in revenue, with net sales rising to ₹3.60 crores (a 12.15% increase QoQ and 2.86% YoY), this growth is considered minimal for a pharmaceutical firm.<BR><BR>The operating margin did show some recovery, reaching 6.11% compared to -13.08% in Q3 FY26, indicating a marginal operational improvement. However, the profit after tax (PAT) margin remains deeply negative at -10.00%, although it improved from -16.82% in the previous quarter.<BR><BR>Overall, the company's financial performance reveals ongoing struggles with profitability and operational efficiency. The persistent net losses, combined with a significant decline in revenue over the past fiscal year, raise concerns about its long-term viability. Additionally, the stock has significantly underperformed compared to the broader market, reflecting investor skepticism about its recovery prospects. Thus, the latest results can be characterized as concerning, with multiple red flags indicating that the company is still facing substantial challenges.

How has been the historical performance of Decipher Labs?

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

Is Decipher Labs overvalued or undervalued?

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

What is the technical trend for Decipher Labs?

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

Who are the top shareholders of the Decipher Labs?

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Decipher Labs declared dividend?

No Dividend History Available